Life Style

Researchers are developing a multivalent vaccine for COVID-19 and influenza

Researchers at Duke University in the United States have conducted annual influenza strains and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Preclinical results showed that the vaccine protected mice from both SARS-CoV-2 and influenza.

Vaccines can be a cost-effective means of preventing influenza and coronavirus infections in countries where expensive vaccine production is not possible.

Influenza-based multivalent vaccines could be a generalized approach to reducing the time and manufacturing requirements of developing new vaccines. Because current influenza vaccines are composed of three or four different strains, this approach can be even more multiplexed than eliciting a response to two pathogens, “the researchers write. ..

Research on “influenza virus particles possessed as a respiratory disease vaccine in combination with SARS-CoV-2 spike RBD” bioRxiv* Servers and articles have been peer reviewed.

Seasonal combination vaccine provokes antibody response against both viruses

Researchers have created a recombinant influenza A virus (IAV) gene platform that allows influenza virus to act as a vector that packages SARS-CoV-2. Spike protein.. The goal of the seasonal combination vaccine is to target both influenza virus and SARS-CoV-2.

To test the efficacy of the vaccine, they primed naive mice with either a wild-type strain or a combination vaccine. Three weeks later, the animals were given intramuscular booster shots. Inactivated vaccine Or a control shot. Researchers collected blood samples two weeks after booster immunization to assess antibody activity.

High serum IgG levels were observed in vaccinated mice when blood samples were exposed to either the IAV hemagglutinin (HA) protein or the SARS-CoV-2 receptor binding domain (RBD) protein. In addition, there was no difference in IgG reactivity between the two vaccine groups, even when the vaccine contained low IAV HA protein.

High antibody binding activity was associated with high neutralizing activity against H1N1IAV.

Serum samples from vaccinated mice showed stronger antibody responsiveness to the SARS-CoV-2 receptor binding domain than mice vaccinated with wild-type IAV. In addition, mice receiving the combination vaccine had higher neutralizing activity than mice receiving the wild-type IAV vaccine group.

Therefore, the viral IAV / SARS CoV-2 combination vaccine is immunogenic and elicits a potentially protective humoral response to SARS-CoV-2. This additional antigenicity is delivered at no apparent cost to the immune response directed to IAV, validating the platform concept of a viral particle-based combination vaccine, “the researchers conclude.

DPT vaccine protects against influenza and severe COVID-19 disease

Researchers have investigated how the vaccine deals with deadly viral doses. This is enough to cause a serious illness.

They infected C57BL / 6 mice and were given vaccines or controls. The results showed that the mice in the control group lost weight rapidly and died. However, mice vaccinated with wild-type IAV and recombinant IAV / SARS-CoV-2 vaccines did not experience weight loss and did not succumb to infection.

Experiments were repeated in transgenic mice expressing the human SARS-CoV-2 receptor — increased susceptibility to serious disease from the wild-type SARS-CoV-2 strain. Two weeks after receiving the booster shot, a lethal dose of SARS-CoV-2 was administered intranasally.

Mice vaccinated with wild-type IAV experienced weight loss and death. In contrast, mice receiving the combination vaccine were protected from infection. Researchers found that the lack of infection in mice with the DPT vaccine Neutralizing antibody..

Future work

Creating a combination vaccine to combat the influenza virus and SARS-CoV-2 helps increase production by reducing vaccine development time and manufacturing costs.

Researchers say some questions need to be addressed before the vaccine can be introduced into humans. Future work will need to test whether the receptor-binding domain (RBD) component of the peplomer is the most suitable antigen, or whether the complete peplomer is more effective.

In addition, viral genetic engineering reduces viral yields, and future studies need to assess how important this production is for vaccine production. Studies with different influenza viruses or HA proteins are also needed to see if the vaccine can use different influenza strains that can properly integrate the SARS-CoV-2 receptor binding domain.

*Important Notices

bioRxiv Publish preliminary scientific reports that should not be considered definitive as they are not peer-reviewed, guide clinical practice / health-related behaviors, and should not be treated as established information.

Researchers are developing a multivalent vaccine for COVID-19 and influenza

Source link Researchers are developing a multivalent vaccine for COVID-19 and influenza

Back to top button